Search research articles
Contact Us
Filters
Showing results (181-190 of 207) with videos related to
Page
of 21
Sort By:
JAMA
|
July 20, 2010
Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel
Melanie A Thompson, Judith A Aberg, Pedro Cahn, et al.
The Journal of Infectious Diseases
|
September 2, 2025
VH3810109 Efficacy, Safety, Pharmacokinetics, and Incidence of Anti-drug Antibodies in Adults With HIV-1 Naive to Antiretroviral Therapy: BANNER Study Results
Peter Leone, Alejandro Ferro, Charlotte-Paige Rolle, et al.
Lancet (London, England)
|
November 14, 2018
Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials
Pedro Cahn, Juan Sierra Madero, José Ramón Arribas, et al.
The Lancet. HIV
|
October 31, 2020
Safety and efficacy of the HIV-1 attachment inhibitor prodrug fostemsavir in heavily treatment-experienced individuals: week 96 results of the phase 3 BRIGHTE study
Max Lataillade, Jacob P Lalezari, Michael Kozal, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
March 13, 2025
Doravirine/islatravir (100/0.75 mg) once-daily compared to bictegravir/emtricitabine/tenofovir alafenamide as initial HIV-1 treatment: 48-week results from a phase 3, randomized, controlled, double-blind, non-inferiority trial
Jürgen K Rockstroh, Roger Paredes, Pedro Cahn, et al.
Lancet (London, England)
|
July 9, 2013
Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study
Pedro Cahn, Anton L Pozniak, Horacio Mingrone, et al.
The Pediatric Infectious Disease Journal
|
March 14, 2003
Forty-eight-week evaluation of lopinavir/ritonavir, a new protease inhibitor, in human immunodeficiency virus-infected children
Xavier Sáez-Llorens, Avyi Violari, Carl O Deetz, et al.
Journal of the International AIDS Society
|
March 10, 2012
Gender-sensitive reporting in medical research
Shirin Heidari, Quarraisha Abdool Karim, Judith D Auerbach, et al.
Journal of the International AIDS Society
|
July 26, 2018
Expert consensus statement on the science of HIV in the context of criminal law
Françoise Barré-Sinoussi, Salim S Abdool Karim, Jan Albert, et al.
Antiviral Therapy
|
September 6, 2002
A randomized clinical trial comparing nelfinavir or nevirapine associated to zidovudine/lamivudine in HIV-infected naive patients (the Combine Study)
Daniel Podzamczer, Elena Ferrer, Ezequiel Consiglio, et al.
Page
of 21
Search research articles
Search
Showing results (181-190 of 207) with videos related to
Sort By:
Page
of 21
JAMA
|
July 20, 2010
Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel
Melanie A Thompson, Judith A Aberg, Pedro Cahn, et al.
The Journal of Infectious Diseases
|
September 2, 2025
VH3810109 Efficacy, Safety, Pharmacokinetics, and Incidence of Anti-drug Antibodies in Adults With HIV-1 Naive to Antiretroviral Therapy: BANNER Study Results
Peter Leone, Alejandro Ferro, Charlotte-Paige Rolle, et al.
Lancet (London, England)
|
November 14, 2018
Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials
Pedro Cahn, Juan Sierra Madero, José Ramón Arribas, et al.
The Lancet. HIV
|
October 31, 2020
Safety and efficacy of the HIV-1 attachment inhibitor prodrug fostemsavir in heavily treatment-experienced individuals: week 96 results of the phase 3 BRIGHTE study
Max Lataillade, Jacob P Lalezari, Michael Kozal, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
March 13, 2025
Doravirine/islatravir (100/0.75 mg) once-daily compared to bictegravir/emtricitabine/tenofovir alafenamide as initial HIV-1 treatment: 48-week results from a phase 3, randomized, controlled, double-blind, non-inferiority trial
Jürgen K Rockstroh, Roger Paredes, Pedro Cahn, et al.
Lancet (London, England)
|
July 9, 2013
Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study
Pedro Cahn, Anton L Pozniak, Horacio Mingrone, et al.
The Pediatric Infectious Disease Journal
|
March 14, 2003
Forty-eight-week evaluation of lopinavir/ritonavir, a new protease inhibitor, in human immunodeficiency virus-infected children
Xavier Sáez-Llorens, Avyi Violari, Carl O Deetz, et al.
Journal of the International AIDS Society
|
March 10, 2012
Gender-sensitive reporting in medical research
Shirin Heidari, Quarraisha Abdool Karim, Judith D Auerbach, et al.
Journal of the International AIDS Society
|
July 26, 2018
Expert consensus statement on the science of HIV in the context of criminal law
Françoise Barré-Sinoussi, Salim S Abdool Karim, Jan Albert, et al.
Antiviral Therapy
|
September 6, 2002
A randomized clinical trial comparing nelfinavir or nevirapine associated to zidovudine/lamivudine in HIV-infected naive patients (the Combine Study)
Daniel Podzamczer, Elena Ferrer, Ezequiel Consiglio, et al.
Page
of 21